3-叔丁基-5-(4-甲基咪唑-1-基)苯胺 | 1290090-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-叔丁基-5-(4-甲基咪唑-1-基)苯胺
• 英文名称: 3-(Tert-butyl)-5-(4-methyl-1H-imidazol-1-YL)aniline
• 英文别名: 3-tert-butyl-5-(4-methylimidazol-1-yl)aniline
• CAS: 1290090-22-0
• 化学式: C₁₄H₁₉N₃
• 分子量: 229.325
• InChiKey: BSIMTXPLDUDBPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)benzoic acid 、 3-叔丁基-5-(4-甲基咪唑-1-基)苯胺 在 氰基磷酸二乙酯 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3-tert-butyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)benzamide
  参考文献：
  名称：

  Hybrid compounds as new Bcr/Abl inhibitors

  摘要：

  A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.029
• 作为产物：
  描述：

  4-甲基咪唑 、 3-bromo-5-(tert-butyl)aniline 在 copper(l) iodide 、 1-(5,6,7,8-tetrahydroquinolin-8-yl)ethanone 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-叔丁基-5-(4-甲基咪唑-1-基)苯胺
  参考文献：
  名称：

  Hybrid compounds as new Bcr/Abl inhibitors

  摘要：

  A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.029

文献信息

• 2-Amino-2,3-dihydro-1<i>H</i>-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy
  作者：Dongsheng Zhu、Huocong Huang、Daniel M. Pinkas、Jinfeng Luo、Debolina Ganguly、Alice E. Fox、Emily Arner、Qiuping Xiang、Zheng-Chao Tu、Alex N. Bullock、Rolf A. Brekken、Ke Ding、Xiaoyun Lu

  DOI：10.1021/acs.jmedchem.9b00365

  日期：2019.8.22

  A series of 2-amino-2,3-dihydro-1H-indene-5-carboxamides were designed and synthesized as new selective discoidin domain receptor 1 (DDR1) inhibitors. One of the representative compounds, 7f, bound with DDR1 with a K-d value of 5.9 nM and suppressed the kinase activity with an half-maximal (50%) inhibitory concentration value of 14.9 nM. 7f potently inhibited collagen-induced DDR1 signaling and epithelial-mesenchymal transition, dose-dependently suppressed colony formation of pancreatic cancer cells, and exhibited promising in vivo therapeutic efficacy in orthotopic mouse models of pancreatic cancer.